A Study to Evaluate the Efficacy and Safety of ALH-L1005 in Patients With Chronic Periodontitis
NCT ID: NCT04503746
Last Updated: 2022-08-11
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
117 participants
INTERVENTIONAL
2020-07-16
2021-12-13
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Phase II Clinical Trial of YH23537 in Patients With Chronic Periodontal Disease.
NCT02585596
1% Alendronate Gel in Treatment of Chronic Periodontitis Among Smokers
NCT02168543
HA35 Treatment the Gingival Discomfort as Well as Gingival Redness and Bleeding of Patients With Periodontitis
NCT05765513
Efficacy of Locally Delivred 1.2% Rosuvastatin Gel in Chronic Periodontitis
NCT02283515
Clinical Study of a Formulation Containing Phtalox® in Periodontal Disease
NCT05119283
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Placebo
Placebo twice a day
Placebo
Placebo 4 tablet
ALH-L1005 600 mg
ALH-L1005 300 mg twice a day
ALH-L1005 600mg/day
ALH-L1005 300mg 2 tablet and placebo 2 tablet
ALH-L1005 1,200 mg
ALH-L1005 600 mg twice a day
ALH-L1005 1,200mg/day
ALH-L1005 300mg 4 tablet
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
ALH-L1005 600mg/day
ALH-L1005 300mg 2 tablet and placebo 2 tablet
ALH-L1005 1,200mg/day
ALH-L1005 300mg 4 tablet
Placebo
Placebo 4 tablet
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patients diagnosed with chronic periodontitis
* Patients with 4 teeth and over whose pocket depth is ≥ 4 mm and clinical attachment level is ≥ 3 mm
* Patients who are voluntarily participated in clinical trial
Exclusion Criteria
* Those who had undergone any dental surgical or non-surgical therapy within 3 months prior to the start of the study
* Subjects who are pregnant/ lactating
* Smokers
* Patients who take Anticoagulants or Antiplatelet Agents
* With Systemic diseases that affect periodontal conditions such as: diabetes, hypertension and diseases of immune system
18 Years
78 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
AngioLab, Inc.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
AngioLab, Inc.
Daejeon, Daejeon Gwangyeogsi, South Korea
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
AL102-PDT
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.